{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"}],"units":"Participants"}],"description":"Chimerism analysis of peripheral blood mononuclear cells using PCR for STR/VNTR will be performed post transplant. On each occasion, the peripheral blood will be separated into the T-cell component (using e.g. CD3 selection) and the myeloid component (using e.g.CD14/15 selection) before assessment of chimerism.","groups":[{"description":"Patients receiving Fludarabine, Busulfan, cyclophosphamide and post-transplant cyclophosphamide for a haploidentical donor transplant","id":"OG000","title":"Haploidentical Transplant"}],"paramType":"NUMBER","populationDescription":"18 patients had chimerism drawn at Day 60","reportingStatus":"POSTED","timeFrame":"Day 60","title":"Achievement of >90% (Full) Donor Chimerism in the T-Cell Lineage as Measured by PCR at Day 60 Post-transplantation","type":"SECONDARY","unitOfMeasure":"participants"}